Skip to Content

Join the 'Cetrorelix' group to help and get support from people like you.

Cetrorelix News

Extended Hormone Therapy Doesn't Help Some Prostate Cancer Patients: Study

Posted 23 Sep 2013 by Drugs.com

MONDAY, Sept. 23 – For men with intermediate-risk prostate cancer, long-term hormone therapy after radiation therapy provides no survival advantages compared with short-term hormone therapy, according to a new study. Hormone therapy is used to reduce the levels of male hormones (androgens) such as testosterone, which can stimulate the growth of prostate cancer cells. Researchers examined data from 133 men with intermediate-risk prostate cancer who underwent either long-term hormone therapy (59 patients) or short-term hormone therapy (74 patients) after receiving external beam radiation therapy. Ten-year overall survival was 61 percent in the short-term group and 65 percent in the long-term group, which is not a statistically significant difference. Disease-specific survival was 96 percent in both groups. The study was scheduled for presentation Monday at the annual meeting of the ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Lupron Depot 3.75 mg, Eligard, Leuprolide, Degarelix, Lupron Depot-PED, Supprelin, Trelstar, Vantas, Synarel, Firmagon, Goserelin, Lupron Depot-Gyn, Cetrotide, Trelstar LA, Supprelin LA, Trelstar Depot

Kidney Failure a Possible Risk of Prostate Cancer Hormone Treatment: Study

Posted 18 Jul 2013 by Drugs.com

TUESDAY, July 16 – Hormone therapy for prostate cancer may dramatically increase a man's risk of kidney failure, according to a new study. Use of androgen deprivation therapy was tied to a 250 percent increase in a man's chances of suffering acute kidney injury, Canadian researchers found in a review of more than 10,000 men receiving treatment for early stage prostate cancer. The study appears in the July 17 issue of the Journal of the American Medical Association. Androgen deprivation therapy uses medication or surgery to reduce the amount of male hormones in a man's body, which can then cause prostate cancer cells to shrink or grow more slowly. It is a therapy usually reserved for advanced cases of prostate cancer, said study co-author Laurent Azoulay, a pharmacoepidemiologist at Jewish General Hospital's Lady Davis Institute, in Montreal. Previous research already has linked ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Lupron Depot 3.75 mg, Eligard, Leuprolide, Degarelix, Lupron Depot-PED, Supprelin, Trelstar, Vantas, Synarel, Firmagon, Goserelin, Lupron Depot-Gyn, Cetrotide, Trelstar LA, Supprelin LA, Trelstar Depot

Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients

Posted 6 Dec 2011 by Drugs.com

TUESDAY, Dec. 6 – Men with prostate cancer who are being treated with hormone therapy do not appear to be at increased risk of dying from heart disease, according to a large new review of evidence. Hormone therapy called "androgen deprivation therapy" is a basic of prostate cancer treatment. Several previous studies found that the therapy might increase the risk of cardiac events or even death from prostate cancer. Growing concern led to a U.S. Food and Drug Administration warning and a consensus statement from multiple medical societies, said Dr. Paul Nguyen. But his new research – an analysis of eight randomized clinical trials of more than 4,000 patients, followed for about a decade – reached a different conclusion. "For the majority of men with aggressive prostate cancer, androgen deprivation therapy was associated with better survival and no increased risk of dying from ... Read more

Related support groups: Prostate Cancer, Casodex, Bicalutamide, Degarelix, Firmagon, Flutamide, Cetrotide, Eulexin, Nilutamide, Plenaxis, Abarelix, Antagon, Cetrorelix, Ganirelix, Nilandron

Fertility Drug Shows Potential Against Hot Flashes

Posted 2 Feb 2010 by Drugs.com

WEDNESDAY, Sept. 16 – A powerful fertility drug may have another use for older women: stopping hot flashes. In a letter to the editor in the Sept. 17 issue of the New England Journal of Medicine, researchers from the Netherlands report that in three cases, the injectable medication cetrorelix (Cetrotide) helped ease hot flash symptoms. "It is a very exciting new approach for an extremely common problem with an enormous psychosocial impact that is often ignored or underestimated," said the lead author of the letter, Dr. Hans de Boer, an endocrinologist at Rijnstate Hospital in Arnhem, the Netherlands. Not everyone is convinced that this drug is a viable option for treating menopausal symptoms, however. "This letter describes three cases and has no controls. This drug works on receptors in the brain and no one knows what the long-term consequences might be," said Dr. Lila Nachtigall, ... Read more

Related support groups: Hot Flashes, Postmenopausal Symptoms, Cetrotide, Cetrorelix

Ask a Question

Further Information

Related Condition Support Groups

Ovulation Induction

Related Drug Support Groups

Cetrotide

Cetrorelix Patient Information at Drugs.com